PMGC Holdings Inc.

PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, announced plans to initiate an independent flow cytometry (FACS) analysis program for its engineered probiotic therapeutic candidate, EL-22. The study aims to quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against previously manufactured material. This work is intended to strengthen EL-22's product identity and manufacturing consistency, supporting its development to preserve muscle during weight loss, including with GLP-1 receptor agonists.

PMGC Holdings Inc. announced that its wholly-owned subsidiary, AGA Precision Systems LLC, has entered into a Merger Agreement with another wholly-owned subsidiary, A&B Aerospace, Inc. Under the agreement, AGA will merge into A&B, with A&B Aerospace, Inc. continuing as the surviving entity. The merger involves the cancellation of AGA's membership interests without consideration, while A&B's shares will remain unaffected, with an anticipated effective date of July 2, 2026.

PMGC Holdings Inc.'s wholly owned subsidiary, NorthStrive Defense Tech LLC, has entered into a Standard Exclusive License Agreement with a licensor. This agreement grants NorthStrive Defense Tech a worldwide, non-transferable, exclusive license to develop and commercialize products covered by U.S. Patent No. 12,291,334 and associated know-how in the aerospace and defense fields. The subsidiary will pay a license issue fee, annual maintenance fees, and royalties, and is committed to a development plan with diligence milestones.

PMGC Holdings Inc. announced the merger of its two precision manufacturing portfolio companies, AGA Precision Systems LLC and A&B Aerospace, Inc. A&B Aerospace will be the surviving entity, consolidating the businesses under one corporate structure. This strategic move is expected to streamline operations, share resources, and strengthen PMGC's aerospace manufacturing platform, while both existing sites continue to operate.

PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences Inc., announced positive results from Phase III of its AI-driven drug discovery program with Yuva Biosciences. The program, utilizing Yuva's MitoNova™ AI platform, identified four small-molecule candidates (C1, C2, C3, C4) that significantly increased ANT1 protein expression in primary human skeletal muscle cells. The strongest candidates demonstrated dose-dependent induction, with increases up to +50%. These findings support advancing the compounds for further confirmatory testing and development, focusing on muscle preservation and metabolic stress.

NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., announced positive Phase III results from its AI-driven drug discovery program with strategic partner Yuva Biosciences. Yuva's MitoNova™ AI platform identified four small-molecule candidates (C1, C2, C3, C4) that significantly increased ANT1 protein expression in primary human skeletal muscle cells, a mitochondrial protein central to energy metabolism. The strongest candidates showed dose-dependent induction, with increases up to +50%. These results support advancing the candidates for further confirmatory testing and development in more mature muscle models.

PMGC Holdings Inc., through its wholly-owned subsidiary NorthStrive Biosciences, Inc., announced the filing of two new U.S. patent applications for its EL-22 and EL-32 compounds. These applications expand the company's intellectual property portfolio into potential human pharmaceutical applications, specifically targeting the preservation of lean muscle mass during GLP-1 and obesity-related weight loss. This strategic move aims to address an emerging need in the rapidly growing GLP-1 market, differentiating NorthStrive's portfolio from its previous animal-focused filings.

PMGC Holdings Inc. highlighted that its precision manufacturing subsidiaries, A&B Aerospace, SVM Machining, and AGA Precision Systems, are strategically positioned to capitalize on the rapidly growing space exploration industry. These ITAR-registered and AS9100-certified companies provide advanced precision manufacturing for satellites, launch systems, and space infrastructure. The global space economy reached $613 billion in 2024 and is projected to grow to $1.8 trillion by 2035, presenting a significant opportunity for PMGC to expand its existing 5.7% space-related revenue contribution.

PMGC Holdings Inc. shareholders approved an amendment to the company's bylaws on June 5, 2026, establishing a staggered Board of Directors with two classes (Class I and Class II) serving three-year and one-year terms, respectively, starting after the 2027 Annual Meeting. At the Annual Meeting, all five nominated directors were elected with approximately 99.8% of votes cast in favor. Shareholders also ratified HTL International, LLC as the independent registered public accounting firm for fiscal year 2026 and approved a proposal for potential adjournment, though the company will not adjourn.

PMGC Holdings Inc.'s wholly-owned subsidiary, NorthStrive Defense Tech LLC, announced a binding term sheet for an exclusive, worldwide, sublicensable license in the aerospace and defense field. This license covers a patented multi-domain drone payload technology (U.S. Patent No. 12,291,334) that enables autonomous, buoyancy-assisted transport of payloads across air and water, enhancing efficiency. The agreement also includes a 12-month sponsored research program to develop a working prototype, with NorthStrive holding a first option to license new inventions from this research.